Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Extended Brexpiprazole Treatment for Agitation in Alzheimer's Dementia
NCT03724942Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole orally disintegrating tablet in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 14 weeks. Started Nov 2018; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03724942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724942.